Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTR1E | P28566 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532544 | 0.88 | NPY5R (0.66) | EPHX2EPHX1MEN1LMNAMAPT | |
| SCHEMBL5528440 | 0.85 | FPR2 (0.61) | EPHX2RAB9ASMN1; SMN2POLBFPR2 | |
| SCHEMBL5525522 | 0.85 | NPY5R (0.54) | EPHX2EPHX1MAPTHPGDNPY5R | |
| SCHEMBL5526277 | 0.85 | PARP15 (0.47) | EPHX2EPHX1KMT2AHPGDNPY5R | |
| SCHEMBL5526343 | 0.84 | CTSK (0.60) | EPHX2EPHX1MEN1LMNAMAPT | |
| SCHEMBL5532684 | 0.83 | PARP1 (0.53) | MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL29269296 | 0.81 | KMT2A (0.58) | EPHX2EPHX1MEN1LMNAMAPT | |
| SCHEMBL7354371 | 0.80 | METAP2 (0.70) | EPHX2EPHX1KLK7METAP2METAP1 | |
| SCHEMBL29269301 | 0.79 | KMT2A (0.60) | EPHX2EPHX1MEN1LMNAMAPT | |
| SCHEMBL5520650 | 0.79 | RAB9A (0.61) | EPHX2EPHX1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | EPHX2 1851/4885EPHX1 2078/4885MEN1 4485/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | EPHX2 4537/4885EPHX1 4489/4885MEN1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.